Home Newsfeeds Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase

November 1, 2022

1 minute read

Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy

Fed’s Thomas Barkin And John Williams Among Biggest Macro Catalysts Today

By Lisa Levin

August 30, 4:39 AM

U.S. stocks closed lower on Monday, with the Nasdaq 100 dropping more than 100 points following a decline in Apple Inc (NASDAQ: AAPL) and Microsoft Corporation (NASDAQ: MSFT) shares.

AAPL

Reported Late Tuesday, Hyliion Holdings Updating FY22 Guidance To Include Revenue Of ~$2M And Operating Expenses Of ~$130M

By Benzinga Newsdesk

November 9, 2:11 AM

In the third quarter, the Company recorded $0.5 million in revenue. The Company's third-quarter operating expenses totaled $62.9 million, driven primarily by R&D expenses

HYLN

Market Reaction To Bank Earnings Is Mixed, JPMorgan Analysts Project Further Decline In Net Interest Income

By Surbhi Jain

April 17, 4:15 PM

Banks are coming out of a challenging quarter. Analysts project a further decline in net interest income by approximately 3.6%.

BAC

SciSparc- Clearmind Collaboration Evolves With New International Patent Application For Preventing And Treating Depression

By Benzinga Newsdesk

March 27, 8:56 AM

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,

CMND

Processa Says Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial

Related Posts

Fed’s Thomas Barkin And John Williams Among Biggest Macro Catalysts Today

Reported Late Tuesday, Hyliion Holdings Updating FY22 Guidance To Include Revenue Of ~$2M And Operating Expenses Of ~$130M

Market Reaction To Bank Earnings Is Mixed, JPMorgan Analysts Project Further Decline In Net Interest Income

SciSparc- Clearmind Collaboration Evolves With New International Patent Application For Preventing And Treating Depression